Neurodevelopmental Disorder with Microcephaly, Hypotonia, and Absent Language

1. Disease Information

Overview: Neurodevelopmental disorder with microcephaly, hypotonia, and absent language (NEDMHAL) is an ultra-rare, autosomal recessive proteasome-assembly disorder ("neurodevelopmental proteasomopathy") first described in 2020 in two affected sisters from a consanguineous Pakistani family. It is caused by biallelic pathogenic variants in PSMB1, which encodes the β6 subunit of the 20S core proteasome. Affected individuals present with severe global developmental delay, postnatal microcephaly, axial hypotonia, absent expressive language, short stature, aggressive/behavioral abnormalities, and sensorineural hearing loss. Functional work in patient fibroblasts and a zebrafish model showed that the causal variant destabilizes 20S/26S proteasome assembly, directly linking impaired proteostasis to a human neurodevelopmental phenotype (Ansar et al., 2020, PMID:32129449).

Key identifiers: - OMIM (phenotype): #620038 — NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, HYPOTONIA, AND ABSENT LANGUAGE; NEDMHAL - OMIM (gene): 602017 — PROTEASOME SUBUNIT, BETA-TYPE, 1; PSMB1 - Gene location: Chromosome 6q27 - HGNC: PSMB1 (HGNC:9537) - Inheritance: Autosomal recessive - Suggested MONDO:* a MONDO term for this OMIM-derived entity is expected to exist as a cross-reference to OMIM:620038 (mapping should be confirmed directly against the MONDO release rather than assumed, since it was not independently verified in this search pass). - Orphanet does not appear to carry a dedicated, separately numbered entry distinct from the OMIM phenotype as of this search; the PSMB1 gene page on Orphanet cross-references the associated disorder.

Synonyms: NEDMHAL (OMIM abbreviation); "PSMB1-related neurodevelopmental disorder"; "PSMB1-related proteasomopathy." It is one of a small family of related but molecularly distinct "neurodevelopmental proteasomopathies" (also including disorders caused by PSMC1, PSMC3, PSMD12, and PSMD11) (Cuinat et al., 2024, PMID:39220754).

Data provenance: The disease-defining data derive from a single aggregated case report of an index consanguineous family (two affected sisters, family "F200") combined with functional/mechanistic validation studies (patient-derived cells, in silico protein modeling, and a zebrafish model) — not from large-scale registries or EHR-based aggregation. As of this research pass, no independently published second family was identified; the entity remains defined by this single kindred plus experimental validation.

Sources: - OMIM #620038 — NEDMHAL - OMIM *602017 — PSMB1 - Biallelic variants in PSMB1... — PubMed - Understanding neurodevelopmental proteasomopathies... — PubMed

2. Etiology

Disease causal factors: NEDMHAL is a monogenic, purely genetic disorder — no environmental, infectious, or acquired etiology has been implicated. It is caused by biallelic (homozygous, in the reported family) loss-of-function/destabilizing missense variation in PSMB1.

Genetic risk factors: - Causal variant: A homozygous PSMB1 c.307T>C transition, predicting p.(Tyr103His) (Y103H), was identified in both affected sisters by whole-exome/genome sequencing in the index consanguineous Pakistani family (Ansar et al. 2020, PMID:32129449). The variant affects a highly conserved tyrosine residue. - Molecular consequence: Structural modeling indicated the Y103H substitution "weakens the interactions between PSMB1/β6 and PSMA5/α5 proteasome subunits and thus destabilizes the 20S proteasome complex" — i.e., it is not a simple catalytic-site loss-of-function but an assembly-interface–disrupting variant. - Population frequency: The Y103H variant was absent from gnomAD and from 300 in-house control chromosomes, consistent with a rare, highly penetrant recessive allele (GeneCards/PubMed). - Consanguinity: The proband family was consanguineous, and autosomal recessive transmission with homozygosity was the observed inheritance mechanism — consistent with the broader pattern that recessive, biallelic proteasome-subunit disease alleles are strongly enriched by consanguinity, since core proteasome subunits are highly constrained and most heterozygous loss-of-function variants would be expected to be selected against or, in other proteasome genes (e.g., PSMD12), to instead cause a dominant de novo disorder.

Risk-factor caveat for curation: No independent GWAS, epidemiological, or environmental-exposure risk-factor literature exists for this ultra-rare Mendelian condition; population-level risk-factor databases (GWAS Catalog, PheGenI, CTD) were not found to carry entries for this specific disorder.

Protective factors: None reported. No protective variants or modifier alleles have been described.

Gene-environment interactions: None described; this is not currently modeled as a gene-environment interaction disease.

Sources: - Biallelic variants in PSMB1 — PubMed - PSMB1 gene — GeneCards

3. Phenotypes

Based on the OMIM clinical synopsis and the founding case report, the core phenotype set is:

Severity/progression: The disorder is described as severe and non-progressive/static in its core neurodevelopmental features (developmental delay is profound from infancy rather than regressive), consistent with a primary neurodevelopmental (rather than neurodegenerative) proteasomopathy. Because the condition is known from only two affected siblings, formal frequency percentages (e.g., "80% of patients have X") cannot be computed — features should be curated as present/absent in the reported cases rather than as population frequencies. This is an important curation caveat: standard HPO frequency modifiers (FREQUENT/OCCASIONAL) are not statistically meaningful for an n=2 cohort and should be omitted or explicitly qualified as "observed in both/one of the reported patients."

Quality-of-life impact: Not formally studied (no EQ-5D/SF-36/QOL instrument data identified); qualitatively, the phenotype (absent language, severe ID, non-ambulatory/motor impairment implied by hypotonia) implies a high care-dependency burden, consistent with other severe recessive neurodevelopmental proteasomopathies, but no quantitative QOL data were located.

Sources: - OMIM #620038 clinical synopsis - Biallelic variants in PSMB1 — PubMed

4. Genetic/Molecular Information

Causal gene: PSMB1 (proteasome 20S subunit beta 1; HGNC:9537; NCBI Gene ID 5689; OMIM *602017), chromosome 6q27, 6 exons, encoding the 241-amino-acid, ~26.5 kDa proteasome subunit beta type-1 protein (UniProt P20618).

Pathogenic variant: - Variant: NM_002793 (or equivalent RefSeq) c.307T>C, p.(Tyr103His) - Zygosity/origin: Homozygous, germline, inherited (biallelic transmission from unaffected consanguineous heterozygous parents) - ACMG classification: Reported as pathogenic in the founding functional/genetic study; a ClinVar submission exists for at least a related CDK19 variant in an unrelated condition (not to be confused with NEDMHAL) — curators should confirm the specific ClinVar accession for the PSMB1 Y103H allele directly rather than assume one. - Population frequency: Absent from gnomAD and from 300 local control chromosomes (essentially private/ultra-rare allele). - Functional consequence: Loss-of-function via destabilization of proteasome assembly, not loss of catalytic activity per se — the variant weakens the PSMB1(β6)–PSMA5(α5) subunit-subunit interface required for correct 20S core particle ring assembly, leading to reduced levels of properly assembled 20S and 26S proteasome complexes in patient cells.

Modifier genes: None described.

Epigenetic information: No disease-specific epigenetic (DNA methylation/histone) data were identified for NEDMHAL specifically. (Note: proteasome dysfunction across the broader "neurodevelopmental proteasomopathy" class has been linked to secondary transcriptional/interferon-signature changes — see PSMB1's paralog literature such as PSMD11 and PSMC3, which show increased type-I interferon responses — PMID:39220754 and related PSMC3 literature — but this has not been specifically reported for PSMB1/NEDMHAL itself.)

Chromosomal abnormalities: None reported; this is a single-nucleotide-variant disorder, not a copy-number/structural disorder.

Related genes in the same pathway class (for KB cross-referencing / grouping consideration): PSMB1 sits within the broader emerging "neurodevelopmental proteasomopathy" gene set — PSMC1 (DEE87-adjacent proteasome disorder), PSMC3, PSMD12, and PSMD11 — each causing molecularly distinct but mechanistically related proteostasis disorders (Cuinat et al. 2024, PMID:39220754). Note that CDK19-related developmental and epileptic encephalopathy (DEE87, OMIM #618916) is a different, unrelated gene/disorder that surfaced in searches due to acronym/description similarity and should not be conflated with NEDMHAL/PSMB1 — this is a Named-Entity-Confusion risk worth flagging for curators (a "CDK19" vs "PSMB1" mixup).

Suggested ontology terms: - Gene: hgnc:9537 (PSMB1) - GO Molecular Function: GO:0004298 threonine-type endopeptidase activity (proteasome core particle catalytic activity — note PSMB1/β6 is itself non-catalytic in the mature complex but part of the catalytic ring) - GO Cellular Component: GO:0005839 proteasome core complex; GO:0000502 proteasome complex - GO Biological Process: GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process

Sources: - PSMB1 gene — GeneCards - PSMB1 — NCBI Gene - UniProt P20618 — PSMB1 - Biallelic variants in PSMB1 — PubMed

5. Environmental Information

No environmental, lifestyle, or infectious contributing factors have been described for NEDMHAL — it is a fully penetrant monogenic recessive disorder with no reported environmental modifiers, toxin exposures, or infectious triggers in the literature identified.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Molecular trigger (upstream): Homozygous PSMB1 c.307T>C (p.Y103H) destabilizes the PSMB1(β6)–PSMA5(α5) inter-subunit interface required for correct assembly of the 20S proteasome core particle ring.
2. Proteasome assembly defect: Reduced formation/stability of properly assembled 20S core particles and, consequently, 26S proteasome holoenzymes (20S core + 19S regulatory particle), demonstrated biochemically in patient-derived cells.
3. Impaired proteostasis: Reduced ubiquitin-proteasome system (UPS) capacity for degrading damaged, misfolded, and regulatory ubiquitin-tagged proteins — i.e., impaired protein homeostasis at the cellular level.
4. Neurodevelopmental consequence: In a zebrafish model, CRISPR/Cas9 mutagenesis and morpholino-mediated knockdown of the single zebrafish psmb1 ortholog produced microcephaly, microphthalmia, and an overall reduction in brain size with morphologic brain abnormalities — directly linking proteasome-assembly failure to a small-brain/neurodevelopmental phenotype in vivo.
5. Clinical manifestation: The convergence of impaired neuronal/neural progenitor proteostasis during brain development is proposed to underlie the human phenotype of microcephaly, severe developmental delay/intellectual disability, absent language, and hypotonia.

Cellular processes involved: Ubiquitin-proteasome-mediated protein degradation (GO:0043161); proteostasis/protein quality control; by extension of the broader proteasomopathy literature, secondary innate-immune/interferon pathway dysregulation has been reported for sibling proteasomopathies (PSMC3, PSMD11), suggestive of a shared class-wide mechanism worth watching for in future PSMB1-specific studies, though not yet directly shown for PSMB1.

Protein dysfunction: Not classic misfolding/aggregation of a single client protein, but rather a structural assembly defect in a multi-subunit machine (destabilized inter-subunit ring interface), reducing the abundance/activity of functional 20S/26S proteasome complexes rather than eliminating PSMB1 protein entirely.

Tissue/cell involvement — developing brain: The zebrafish data implicate neural progenitor cells and developing brain tissue as the most proteasome-dependent, disease-relevant compartment, consistent with microcephaly and severe cognitive/language impairment as the dominant human phenotype.

Advanced/omics data: No transcriptomic, proteomic, or single-cell datasets specific to human PSMB1-mutant neural tissue were identified in this search; the zebrafish morphant/mutant model and patient fibroblast proteasome-assembly assays (native gel/glycerol gradient sedimentation-type assays implied by "impaired assembly and function of the 20S and 26S proteasomes") constitute the primary functional dataset.

Suggested ontology terms: - GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process - GO:0000502 proteasome complex - GO:0005839 proteasome core complex - CL: neural progenitor cell (CL:0011020) — implicated by the zebrafish brain-size phenotype, though not directly assayed in human neural tissue - UBERON:0000955 brain (microcephaly/brain-size phenotype)

Sources: - Biallelic variants in PSMB1 — PubMed - Understanding neurodevelopmental proteasomopathies... — PubMed

7. Anatomical Structures Affected

• Organ level: Primary organ affected is the brain/CNS (microcephaly, developmental delay, absent language, hypotonia implying central motor-tone dysregulation). Secondary/associated systems: auditory system (sensorineural hearing loss), skeletal/growth system (short stature, implying either growth-plate or growth-hormone-axis/systemic growth involvement). Behavioral/psychiatric involvement (aggression) implicates frontal-subcortical circuitry, though this is inferred rather than directly imaged/studied.
• Body systems involved: Nervous system (primary); auditory system; skeletal/growth system; behavioral/psychiatric domain.
• Tissue/cell level: Neural tissue, specifically implicating neural progenitor/developing brain tissue based on the zebrafish model; no human neuropathology (biopsy/autopsy) data were identified.
• Subcellular level: Cytoplasmic and nuclear proteasome complexes (GO:0005839 proteasome core complex; the 26S proteasome localizes to both cytoplasm and nucleus).
• Localization/laterality: Microcephaly and developmental phenotypes are generalized/bilateral, not lateralized; no asymmetric findings reported.

Suggested ontology terms: - UBERON:0000955 brain - UBERON:0001846 statoacoustic ganglion / inner ear structures (hearing loss) - UBERON:0002481 bone tissue / growth plate (short stature) - GO:0005634 nucleus; GO:0005737 cytoplasm (proteasome subcellular localization)

Sources: - OMIM #620038

8. Temporal Development

• Onset: Congenital/early-infantile — microcephaly and hypotonia are apparent from infancy; developmental delay becomes evident in the first years of life; language never develops (absent rather than regressed), indicating a prenatal/perinatal neurodevelopmental origin rather than a later degenerative onset.
• Onset pattern: Insidious/static-developmental rather than acute.
• Progression: The core neurocognitive phenotype (severe ID, absent language) is described as a fixed developmental deficit rather than a progressive neurodegenerative course — consistent with a primary developmental (proteostasis-during-neurogenesis) mechanism rather than an ongoing neurodegenerative proteotoxic process, though long-term natural history data beyond the original report were not identified.
• Disease course pattern: Stable/non-progressive impairment (as far as reported); no remission described.
• Disease duration: Chronic, lifelong.
• Critical periods: The zebrafish functional data implicate an early embryonic/neurodevelopmental window (neurogenesis and brain morphogenesis) as the critical period of vulnerability to proteasome-assembly failure, consistent with the congenital/postnatal microcephaly phenotype in humans.

Sources: - OMIM #620038 - Biallelic variants in PSMB1 — PubMed

9. Inheritance and Population

• Epidemiology: NEDMHAL is an ultra-rare disorder; to date it has been reported in only one consanguineous family (two affected sisters). No formal prevalence or incidence estimate exists (effectively "cases in literature" = 2, from a single kindred). This should be curated with measure_type: CASES_IN_LITERATURE and prevalence_class: NOT_YET_DOCUMENTED per the dismech structured-prevalence convention, rather than assigning a numeric rate.
• Inheritance pattern: Autosomal recessive.
• Penetrance: Appears complete in the two reported homozygous individuals (both affected), though the sample size is too small to formally establish penetrance statistics.
• Expressivity: Cannot be assessed robustly from n=2, but the two reported sisters shared the core phenotype, suggesting relatively consistent expressivity, at least within one family/genetic background.
• Genetic anticipation: Not applicable/not described (not a repeat-expansion disorder).
• Germline mosaicism: Not reported.
• Founder effects: Not established; the reported variant arose in a consanguineous Pakistani family, but whether it represents a population-specific founder allele versus a private familial variant has not been determined (absent from gnomAD, so allele-frequency-based founder inference is not currently possible).
• Consanguinity: Central to how this family's disease was unmasked — parental consanguinity produced homozygosity for a rare recessive allele, the classic ascertainment route for ultra-rare autosomal recessive proteasomopathies.
• Carrier frequency: Unknown/not established (variant not present in gnomAD).
• Population demographics: Only described in a Pakistani family to date; no broader ethnic/geographic distribution data exist. Sex ratio: both reported affected individuals are female (sisters), but this reflects the single reported family rather than an established sex bias — X-linked or sex-limited inheritance is not implicated (the gene is autosomal, 6q27).

Sources: - Biallelic variants in PSMB1 — PubMed - OMIM #620038

10. Diagnostics

• Genetic testing (primary diagnostic modality): Diagnosis is established by molecular genetic testing identifying biallelic (homozygous or compound heterozygous) pathogenic variants in PSMB1. In the founding case, diagnosis was made via whole-exome/genome sequencing in a consanguineous family with autozygosity mapping/homozygosity — the standard approach for suspected autosomal recessive neurodevelopmental disorders in consanguineous pedigrees.
• WES/WGS: Appropriate first-tier or confirmatory test, especially given the absence of a well-established, larger gene panel specifically curated for this ultra-rare gene.
• Gene panels: PSMB1 may be included in broader "intellectual disability" or "microcephaly" NGS panels at some diagnostic laboratories, though no dedicated commercial panel was specifically identified in this search.
• Single-gene testing: Feasible via Sanger sequencing once a specific familial variant is known (e.g., for prenatal/carrier testing in a family with a known proband).
• Chromosomal microarray/karyotype/FISH: Not applicable — this is a single-nucleotide-variant disorder, not a CNV/structural disorder, so CMA/karyotype would be expected to be normal and would not establish the diagnosis (useful mainly to exclude alternative CNV etiologies in the differential).
• Functional/biochemical confirmation: In the research setting, proteasome assembly/activity assays (e.g., native/glycerol-gradient analysis of 20S/26S complex formation in patient fibroblasts) were used to functionally validate pathogenicity — this is a research-grade rather than routine clinical diagnostic test.
• Clinical criteria: No formal consensus clinical diagnostic criteria (e.g., DSM/ICD-style) exist for this molecularly defined ultra-rare disorder; diagnosis is genotype-first.
• Differential diagnosis: Given the clinical overlap of "microcephaly + hypotonia + absent language + ID," the differential is broad and includes the many other genetically distinct NEDxxx OMIM entries surfaced in this search (e.g., NEDMISH/FLVCR1, NMIHBA/PRUNE1, NEDHYMS, NEDMILG, NEDTCHAL) as well as other neurodevelopmental proteasomopathies (PSMC1, PSMC3, PSMD12, PSMD11-related disorders) — molecular testing is required to distinguish among these phenotypically overlapping but genetically distinct entities.
• Screening: No population, newborn, or carrier screening program exists for this ultra-rare condition; carrier screening would only be relevant within a known affected family/at-risk consanguineous relatives once the familial variant is identified.

Sources: - Biallelic variants in PSMB1 — PubMed - OMIM search results — related NEDxxx entries

11. Outcome/Prognosis

• Survival/mortality: No mortality data reported; the condition has not been described as life-limiting in itself, though no long-term follow-up/life-expectancy data are available given the very recent description (2020) and small cohort.
• Morbidity/function: Severe, lifelong functional impairment is implied by absent language, severe intellectual disability, and hypotonia — likely translating to significant motor, communicative, and adaptive-functioning impairment, though no formal functional outcome scales (e.g., Vineland, GMFCS) were reported in the identified literature.
• Quality of life: No formal QOL instrument data available.
• Complications: Hearing loss and aggressive behavior are described as associated features/complications affecting management; no other organ-system complications (cardiac, renal, hepatic) have been reported.
• Recovery potential: None described; the neurodevelopmental phenotype (absent language, severe ID) is not expected to normalize, consistent with a developmental rather than treatable/reversible metabolic block.
• Prognostic factors/biomarkers: No validated prognostic biomarkers exist. The broader neurodevelopmental-proteasomopathy review (Cuinat et al. 2024, PMID:39220754) discusses the potential for proteasome activity assays and interferon-signature biomarkers as diagnostic/prognostic tools across this gene class generally, but no PSMB1-specific biomarker has been validated.

Sources: - OMIM #620038 - Understanding neurodevelopmental proteasomopathies... — PubMed

12. Treatment

No disease-specific, mechanism-targeted, or curative therapy exists for NEDMHAL. Management is supportive and symptomatic, following the general pattern for severe monogenic neurodevelopmental disorders:

• Supportive/rehabilitative care:
• Early intervention / developmental therapies for global developmental delay
• Physical therapy for hypotonia and motor development (NCIT:C15302 Physical Therapy)
• Speech/augmentative-communication therapy given absent language (no specific NCIT code identified for AAC; general speech-language therapy concept applies)
• Occupational therapy for adaptive functioning
• Audiology follow-up and hearing aid/amplification evaluation for the sensorineural hearing loss component
• Behavioral management/intervention for aggressive behavior (NCIT:C15747 Supportive Care; behavioral therapy as a general category)
• Genetic counseling: Recommended for families, particularly given the autosomal recessive inheritance and the consanguinity context of the index family (NCIT:C15240 Genetic Counseling); recurrence risk of 25% for future pregnancies in carrier-carrier couples, with prenatal/preimplantation testing feasible once the familial variant is known.
• Pharmacotherapy: No PSMB1/NEDMHAL-specific pharmacotherapy exists. No proteasome-activity-modulating drug has been reported in a clinical or preclinical therapeutic context for this specific disorder in the literature identified (note: proteasome inhibitors, such as bortezomib, are used therapeutically in oncology/plasma-cell disorders for the opposite problem of excess proteasome activity, and are not relevant/applicable here — indeed pharmacologically boosting rather than inhibiting proteasome activity would be the theoretically desired direction, but no such approved or investigational agent for this indication was found).
• Experimental/clinical trials: No registered clinical trials specific to PSMB1-NEDMHAL were identified (searches of ClinicalTrials.gov were not directly performed in this pass but no trial references surfaced in general searches).
• Advanced therapeutics (gene/RNA-based): None reported or in development for this ultra-rare indication as of this search.

Sources: - OMIM #620038 - Understanding neurodevelopmental proteasomopathies... — PubMed

13. Prevention

• Primary prevention: Not applicable in the traditional sense (not preventable via risk-factor modification, since it is a fully genetic recessive condition); the only "primary prevention" avenue is reproductive genetic counseling and reduction of consanguineous mating risk awareness in at-risk families, or use of preimplantation genetic testing (PGT-M) once a familial pathogenic variant is identified.
• Secondary prevention: Early diagnosis via genetic testing in at-risk consanguineous families or in infants presenting with unexplained microcephaly + hypotonia + developmental delay, enabling earlier initiation of supportive/developmental therapies.
• Genetic counseling: The principal "prevention" lever available — informing carrier parents of 25% recurrence risk per pregnancy, and offering prenatal diagnosis (chorionic villus sampling/amniocentesis with targeted variant testing) or PGT-M in future pregnancies once the family's causal variant is known (NCIT:C15240 Genetic Counseling).
• Carrier/prenatal screening: No population-based carrier screening exists for this ultra-rare, single-family-described gene; targeted familial carrier testing is the only applicable screening modality currently.
• Public health/behavioral/immunization/prophylaxis: Not applicable — no infectious, environmental, or behavioral prevention avenue exists for this monogenic disorder.

14. Other Species / Natural Disease

• Taxonomy: No naturally occurring PSMB1-related disease has been reported in non-human species (companion animals, wildlife); OMIA and veterinary literature searches did not surface a natural veterinary corollary in this research pass.
• Orthologous gene: Psmb1 (mouse, MGI:104884, synonym Lmpc5); zebrafish psmb1 ortholog (used experimentally, see below). NCBI Gene entries exist for the mouse ortholog.
• Comparative biology / model use: The zebrafish ortholog was used specifically to model human disease (see Section 15) rather than representing a naturally occurring disease in that species.
• Zoonotic potential/cross-species transmission: Not applicable — this is a non-infectious monogenic disorder.

Sources: - Psmb1 — MGI Mouse Gene Detail

15. Model Organisms

• Zebrafish (Danio rerio) — primary disease model used to validate pathogenicity:
• Both CRISPR/Cas9-mediated mutagenesis and morpholino-mediated knockdown of the single zebrafish psmb1 ortholog were performed by Ansar et al. (2020, PMID:32129449).
• Phenotype recapitulation: Both approaches produced microcephaly and microphthalmia, with an "overall reduction in brain size and morphologic brain abnormalities" — directly recapitulating the core human microcephaly/neurodevelopmental phenotype, supporting a RECAPITULATES model-mechanism link (fidelity likely MODERATE-to-HIGH for the brain-size/microcephaly phenotype specifically; the model cannot assess higher-order human phenotypes such as absent language or aggressive behavior, which have no zebrafish behavioral correlate — a HUMAN_MODEL_MISMATCH-type caveat for those specific features).
• Limitations: Zebrafish lack the capacity to model human language/speech or complex behavioral phenotypes (aggression), and morpholino knockdown carries well-known off-target/specificity caveats partially mitigated here by the concordant CRISPR mutant phenotype.
• Patient-derived human cells (fibroblasts): Used to directly demonstrate impaired 20S/26S proteasome assembly and function biochemically — a MEASURES/RECAPITULATES-type human cellular model rather than an animal model, providing the most direct (HIGH fidelity, since it is genuinely patient-derived) mechanistic evidence.
• Mouse: No PSMB1-specific mouse knockout/disease model was identified in this search (searches for Psmb1 mouse knockout phenotype data did not return a dedicated publication describing embryonic lethality or a neurodevelopmental phenotype specifically for Psmb1, in contrast to sibling proteasome subunits such as Psmc1, Psmc3, Psmc4, Psmd4, Psmd11, and Psmg1, which have documented embryonic-lethal or neuropathological mouse knockout phenotypes reported in the literature). Given that PSMB1 is a core, obligate structural subunit of the proteasome, a complete knockout would plausibly be embryonic lethal by analogy to these other subunits, but this has not been directly confirmed in the literature identified here and should not be asserted without a direct source.
• In vitro/other systems: No organoid, iPSC-derived, or additional invertebrate (Drosophila, C. elegans, yeast) PSMB1-disease-modeling studies specific to NEDMHAL were identified, though proteasome biology broadly is heavily studied in yeast and Drosophila systems for basic mechanism (not disease-modeling) purposes.

Sources: - Biallelic variants in PSMB1 — PubMed - Psmb1 — MGI Mouse Gene Detail

Summary and Curation Notes

NEDMHAL (OMIM #620038) is an ultra-rare autosomal recessive proteasome-assembly disorder caused by biallelic PSMB1 (β6 subunit) variants, defined to date by a single consanguineous family (two affected sisters) carrying a homozygous p.(Tyr103His) variant that destabilizes 20S/26S proteasome assembly (Ansar et al., 2020, Human Molecular Genetics, PMID:32129449). It belongs to an emerging disease class termed "neurodevelopmental proteasomopathies," alongside PSMC1-, PSMC3-, PSMD11-, and PSMD12-related disorders (Cuinat et al., 2024, Genes & Diseases, PMID:39220754). Key curation cautions: (1) do not conflate this with CDK19-related DEE87 (OMIM #618916), a phenotypically similar-sounding but molecularly and genetically distinct disorder that surfaced repeatedly in searches — a clear Named-Entity-Confusion risk; (2) given the n=2 evidence base, avoid assigning HPO frequency qualifiers or numeric prevalence rates not supported by the primary literature — use CASES_IN_LITERATURE/NOT_YET_DOCUMENTED-type structured prevalence values instead; (3) the mouse Psmb1 knockout phenotype was not confirmed in this search and should not be asserted as embryonic lethal without a direct citation; (4) treatment content should be limited to genuinely supportive/symptomatic and genetic-counseling interventions, since no disease-modifying therapy exists.

All PMIDs and ontology-term suggestions above should be independently re-verified against PubMed abstracts, OMIM, gnomAD, and OAK/ontology lookups per standard dismech curation SOP before being committed to a KB entry — several details here (e.g., exact HPO CURIEs, precise ClinVar accession, MONDO cross-reference ID) were inferred/recalled rather than directly confirmed against a live ontology browser in this research pass, and are flagged accordingly above.

Sources: - OMIM #620038 — NEDMHAL - OMIM *602017 — PSMB1 - Biallelic variants in PSMB1 encoding the proteasome subunit β6... — PubMed (PMID:32129449) - Understanding neurodevelopmental proteasomopathies as new rare disease entities — PubMed (PMID:39220754) - Understanding neurodevelopmental proteasomopathies... — ScienceDirect full text - PSMB1 gene — GeneCards - PSMB1 — NCBI Gene - PSMB1 — UniProt P20618 - Psmb1 — MGI Mouse Gene Detail - Biallelic variants in PSMB1 — Human Molecular Genetics (Oxford Academic)

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.